This is attributable to improvements in early-stage diagnosis; the probability of HCC diagnosed at early (BCLC A/0) stage would increase to 81.3% for those who undergo 6-monthly US surveillance with AFP compared with 47.0% in the cohort with no surveillance. Here, AFP is linked to hepatocellular carcinoma.